159 related articles for article (PubMed ID: 35263200)
41. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
42. Suppression of adriamycin resistance in osteosarcoma by blocking Wnt/β-catenin signal pathway.
Wu BQ; Cao Y; Bi ZG
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3185-3192. PubMed ID: 28770967
[TBL] [Abstract][Full Text] [Related]
43. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
44. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
[TBL] [Abstract][Full Text] [Related]
45. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
46. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods.
Liu Y; Zeng L; Zhang S; Zeng S; Huang J; Tang Y; Zhong M
Med Oncol; 2013 Jun; 30(2):528. PubMed ID: 23504336
[TBL] [Abstract][Full Text] [Related]
47. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
[TBL] [Abstract][Full Text] [Related]
49. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Zheng W; Lin Q; Issah MA; Liao Z; Shen J
BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
[TBL] [Abstract][Full Text] [Related]
51. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
52. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
[TBL] [Abstract][Full Text] [Related]
53. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
Peng W; Wu J; Feng J
Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
[TBL] [Abstract][Full Text] [Related]
54. Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin.
Zhang X; Chen J; Ai Z; Zhang Z; Lin L; Wei H
Life Sci; 2018 Dec; 215():1-10. PubMed ID: 30473023
[TBL] [Abstract][Full Text] [Related]
55. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
[TBL] [Abstract][Full Text] [Related]
56. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH
Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832
[TBL] [Abstract][Full Text] [Related]
57. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
[TBL] [Abstract][Full Text] [Related]
58. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
59. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
60. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]